LCTX Profile
Lineage Cell Therapeutics, Inc., based in Carlsbad, California, is a clinical-stage biotechnology firm focused on pioneering cell therapies aimed at treating degenerative diseases globally. Established in 1990 and previously known as BioTime, Inc., the company rebranded as Lineage Cell Therapeutics, Inc. in August 2019 to reflect its strategic shift towards advancing innovative therapeutic solutions.
At the forefront of Lineage's research and development efforts are several promising therapies. One notable candidate is OpRegen, a cell replacement therapy targeting retinal pigment epithelium cells. Currently undergoing Phase I/IIa clinical trials, OpRegen aims to address dry age-related macular degeneration, a leading cause of vision loss in aging populations.
Another key initiative is OPC1, an oligodendrocyte progenitor cell therapy being evaluated in Phase I/IIa multicenter clinical trials for treating acute spinal cord injuries. This therapy holds significant promise in addressing the debilitating effects of such injuries by promoting neural repair and regeneration.
Furthermore, Lineage is advancing VAC2, an allogeneic cancer immunotherapy leveraging antigen-presenting dendritic cells. In Phase I clinical trials, VAC2 targets non-small cell lung cancer, highlighting the company's commitment to innovating in the oncology space and potentially transforming cancer treatment paradigms.
Beyond its clinical pipeline, Lineage Cell Therapeutics remains dedicated to expanding therapeutic options across diverse medical domains including retinal diseases, neurological disorders, and oncological conditions. The company's collaboration with Orbit Biomedical, Ltd. underscores its collaborative approach to advancing cutting-edge therapies that aim to improve patient outcomes and quality of life globally.
|
